Urinary Tract Infection Treatment Market: Improving access to essential drugs & rising public awareness fueling revenue growth: Global Industry Analysis and Opportunity Assessment, 2016 – 2026
- REP-GB-1340
- 2016-06-23
- Category: Healthcare, Pharmaceuticals and Medical devices
- 229 Pages
- Format:
Urinary tract infection (UTI) occurs in the bladder, urethra, ureter, and kidneys due to colonization of microbial pathogens in these parts. UTI infections can be complicated or uncomplicated, based on the severity of infection. Amoxicillin is a penicillin antibiotic used to treat UTIs and is one of the most commonly prescribed antibiotic for uncomplicated UTIs. Urinary tract infection is among the most common bacterial infections affecting millions of persons worldwide. Recurrent urinary tract infection is a major health issue in females across the globe. Patients with urinary catheter or spinal cord injury are most likely to contract complicated UTIs.
Among non-institutionalized geriatric population, UTIs are the second-most common infection and estimated to account for around 25% of all bacterial infections.
Market Value and Forecast
The global Urinary tract infection treatment market was valued at US$ 9.2 Bn in 2015, and is projected to expand at a CAGR of 2.1% over forecast period 2016–2026, owing to increasing incidence of UTIs and recurring UTIs, increasing use of urinary catheters, and other drainage devices.
Drivers and Trends
Incidence of chronic diseases are on the rise across the globe. Population with chronic diseases such as diabetes mellitus, chronic institutional residence, neurologic conditions, and chronic indwelling urinary catheterization are more susceptible to developing complicated urinary tract infections. These factors are expected to increase the number of UTI patients and is expected to boost growth of the UTI treatment market over the forecast period. Introduction of combination products to combat multi-drug resistant bacteria and expending indications for existing drugs are some key factors positively affecting market growth.
Analysis by Region
The global urinary tract infection treatment market has been segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), and Japan and Middle East & Africa (MEA). In terms of value, the APEJ market has been estimated to dominate the global urinary tract infection treatment market in 2016, and is expected to witness highest CAGR of 2.4% over the forecast period. Markets in MEA, North America, and Western Europe are estimated to register higher CAGRs as compared to other regional markets. Revenue from the North America market is expected to expand at a CAGR of 2.0% over the forecast period. In North America, the quinolones segment is expected to register a CAGR of 2.6% to reach value of US$ 695.4 Mn by 2026 end.
Analysis by Drug Type
The global urinary tract infection treatment market is segmented into penicillin & combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides, azoles and amphotericin B, tetracycline, nitrofurans, and other segments. Penicillin & combinations segment is further sub-segmented into amoxicillin, amoxicillin & clavulanate potassium, and others. Quinolones segment is further sub-segmented into ciprofloxacin, levofloxacin, nalidixic acid, norfloxacin, and others. Cephalosporin segment is further sub-segmented into ceftriaxone, cefuroxime, cefixime, and cephalexin. Aminoglycoside antibodies segment is further sub-segmented into amikacin and gentamicin. Quinolones segment is estimated to account for maximum revenue share in the global urinary tract treatment market.
Analysis by Indication
By indication, the global urinary tract infection treatment market is segmented into complicated urinary tract infection, recurring complicated urinary tract infection, uncomplicated urinary tract infection, and neurogenic bladder infection. The neurogenic bladder infections indication segment is expected to expand at a CAGR of 2.6% in terms of revenue over the forecast period. The uncomplicated urinary tract infection segment was estimated in 2015 to dominate the overall urinary tract infection treatment market and expected to expand at a healthy CAGR over the forecast period.
Analysis by Distribution Channel
By distribution channel, the global urinary tract infection treatment market is segmented into hospital pharmacies, gynecology and urology clinics, drug store, retail pharmacies, and online drug stores. The online drug stores distribution channel segment is expected to expand at a CAGR of 2.8% in terms of revenues over the forecast period. The retail pharmacies is estimated to dominate the overall urinary tract infection market and expected to expand at a healthy CAGR over the forecast period
Competitive Landscape
Some of the key players identified in the global urinary tract infection market report include Johnson and Johnsons Private Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., Bayer AG, GlaxoSmithKline Pharmaceuticals Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and AstraZeneca plc. The report offers valuable insights into company-specific strategies related to the global urinary tract infection market, market consolidation initiatives, and analyses of the various market players’ specific strengths, weaknesses, opportunities, and threats.
An in-depth assessment of the urinary tract infection treatment market is showcased in the research report published by Future Market Insights (FMI) for a period of ten years from 2016 to 2026. The report states that the urinary tract infection treatment market is projected to register a CAGR of 2.1 percent during the period of forecast. The research study is an effective compilation of necessary information pertaining to the market for greater understanding of the future avenues of the market. The study provides meaningful insights with the help of the information presented in light of the current market scenario of the urinary tract infection treatment market.
Report Description
The study highlights the market influencers in major regions across the globe which are expected to impact the current environment and future circumstances of the urinary tract infection treatment market over the forecast period. This research publication by FMI intends to offer insights into advancements in the urinary tract infection treatment market that are capable of transforming the health-care industry into an improved sector.
Extensive research conducted by experienced analysts with well-scrutinized data resulting in qualitative and quantitative insights are major highlights of the report. The urinary tract infection treatment market report commences with the executive summary defining the urinary tract infection and the medication used for its treatment. This section identifies the indications for urinary tract infection proceeded by an overview of the urinary tract infection treatment market. The overview section of the market includes an assessment of the market restraints, drivers, and opportunities followed by the key market trends that are expected to influence the urinary tract infection treatment market. The last section is devoted to an effective assessment of the players in the urinary tract infection treatment market.
Urinary Tract Infection Treatment Market Introduction
The market research study provided by FMI helps the reader attain a greater understanding of the market with a market introduction at the beginning of the report that comprises of a brief market taxonomy and definition. Furthermore, the study highlights key drugs types providing an overview of its comprehensive understanding. Followed by this, the report gives information of the drugs and defines the resistant timeline and clinical trials of the same. The market introduction section is a brief overview of the entire research study that provides necessary analysis of the market influencers and their impact on the current and future market scenario.
Market Segmentation
The research report segments the urinary tract infection treatment market on the basis of indication, drug type, and distribution channel. The report consists of necessary information pertaining to each segment with well-analyzed insights regarding market size and market share analysis. The study effectively covers year-over-year growth rate projection, basis share analysis and absolute ($) opportunity for the period of forecast. Information pertaining to market attractiveness further highlights the opportunities that the urinary tract infection treatment market holds in the future. Furthermore, the inclusion of figures charts and tables provide a precise understanding of the market to the reader. The regional segregation of the market helps evaluate the global scenario of urinary tract infection treatment with numbers stating the scale of each region pertaining to this market. Major markets assessed in this report include North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, and MEA. It helps the reader evaluate the most lucrative regions and provides an overview of the other regions in the picture.
Competitive Analysis
The final section of the report comprises a competitive landscape that provides a dashboard view for the report audience to give a better understanding of the players. This section highlights the strategic actions and key developments carried out by these market players along with the individual company profiles. The inclusion of SWOT analysis of major market players is a key highlight of the report. Major players in the market include GlaxoSmithKline Pharmaceuticals Ltd., Johnson and Johnsons Private Ltd., Boehringer Ingelheim GmbH, Novartis AG., Cipla Ltd., Bayer AG, Pfizer Inc., F.Hoffmann-La Roche Ltd., and AstraZeneca plc.
Urinary Tract Infections Market Reports - Table of Contents
1.Assumptions and Acronyms Used
2.Research Methodology
3.Executive Summary
4.Urinary Tract Infection Treatment Market Overview
4.1. Introduction
4.1.1.Urinary Tract Infection Treatment Market Taxonomy
4.1.2.Urinary Tract Infection Treatment Market Definition
4.1.3.Urinary Tract Infection Treatment Market Drug Type Overview
4.1.4.Global Antibiotic Drugs Availability and Resistant Timeline
4.1.5.Clinical Trials
4.2. Urinary Tract Infection Treatment Market Dynamics
4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunity
4.2.4.Trends
4.3. Survey Analysis
4.4. Epidemiology Overview
4.5. PEST Analysis
5.Global Urinary Tract Infection Treatment Market Analysis, By Drug Type
5.1. Introduction
5.1.1.Y-o-Y Growth Comparison, By Drug Type
5.1.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
5.1.3.Market Attractiveness Analysis, By Drug Type
5.2. Market Forecast, By Drug Type
5.2.1.Penicillin & Combinations
5.2.1.1. Absolute $ Opportunity
5.2.1.2. Market Value Forecast
5.2.1.3. Amoxicillin
5.2.1.4. Amoxicillin+ Clavulanate Potassium
5.2.1.5. Others
5.2.2.Quinolones
5.2.2.1. Absolute $ Opportunity
5.2.2.2. Market Value Forecast
5.2.2.3. Ciprofloxacin
5.2.2.4. Levofloxacin
5.2.2.5. Nalidixic acid
5.2.2.6. Norfloxacin
5.2.2.7. Others
5.2.3.Cephalosporin
5.2.3.1. Absolute $ Opportunity
5.2.3.2. Market Value Forecast
5.2.3.3. Cefuroxime
5.2.3.4. Ceftriaxone
5.2.3.5. Cefixime
5.2.3.6. Cephalexin
5.2.4.Aminoglycoside Antibiotics
5.2.4.1. Absolute $ Opportunity
5.2.4.2. Market Value Forecast
5.2.4.3. Amikacin
5.2.4.4. Gentamicin
5.2.5.Sulphonamides
5.2.5.1. Absolute $ Opportunity
5.2.5.2. Market Value Forecast
5.2.5.3. Sulfamethoxazole + Trimethoprim
5.2.6.Azoles and Amphotericin B
5.2.6.1. Absolute $ Opportunity
5.2.6.2. Market Value Forecast
5.2.7.Tetracycline
5.2.7.1. Absolute $ Opportunity
5.2.7.2. Market Value Forecast
5.2.7.3. Doxycycline
5.2.8.Nitrofurans
5.2.8.1. Absolute $ Opportunity
5.2.8.2. Market Value Forecast
5.2.8.3. Nitrofurantoin
5.2.9.Others
5.2.9.1. Absolute $ Opportunity
5.2.9.2. Market Value Forecast
6.Global Urinary Tract Infection Treatment Market Analysis, By Distribution Channel
6.1. Introduction
6.1.1.Y-o-Y Growth Comparison, By Distribution Channel
6.1.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
6.1.3.Market Attractiveness Analysis, By Distribution Channel
6.2. Market Forecast, By Distribution Channel
6.2.1.Hospital Pharmacies
6.2.1.1. Absolute $ Opportunity
6.2.1.2. Market Value Forecast
6.2.2.Gynecology and Urology Clinics
6.2.2.1. Absolute $ Opportunity
6.2.2.2. Market Value Forecast
6.2.3.Drug Store
6.2.3.1. Absolute $ Opportunity
6.2.3.2. Market Value Forecast
6.2.4.Retail Pharmacies
6.2.4.1. Absolute $ Opportunity
6.2.4.2. Market Value Forecast
6.2.5.Online Drug Stores
6.2.5.1. Absolute $ Opportunity
6.2.5.2. Market Value Forecast
7.Global Urinary Tract Infection Treatment Market Analysis, By Indication
7.1. Introduction
7.1.1.Y-o-Y Growth Comparison, By Distribution Channel
7.1.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
7.1.3.Market Attractiveness Analysis, By Distribution Channel
7.2. Market Forecast, By Distribution Channel
7.2.1.Complicated UTI
7.2.1.1. Absolute $ Opportunity
7.2.1.2. Market Value Forecast
7.2.2.Recurring Complicated UTI
7.2.2.1. Absolute $ Opportunity
7.2.2.2. Market Value Forecast
7.2.3.Uncomplicated UTI
7.2.3.1. Absolute $ Opportunity
7.2.3.2. Market Value Forecast
7.2.4.Neurogenic Bladder Infections
7.2.4.1. Absolute $ Opportunity
7.2.4.2. Market Value Forecast
7.2.4.3.
8.Global Urinary Tract Infection Treatment Market Analysis, By Region
8.1. Introduction
8.1.1.Y-o-Y Growth Projections, By Region
8.1.2.Market Share & Basis Point (BPS) Analysis, By Region
8.1.3.Regional Attractiveness Analysis
8.2. Market Forecast, By Region
8.2.1.North America Market Value Forecast
8.2.2.Latin America Market Value Forecast
8.2.3.Europe Market Value Forecast
8.2.4.Eastern Europe Market Value Forecast
8.2.5.APEJ Market Value Forecast
8.2.6.Japan Market Value Forecast
8.2.7.MEA Market Value Forecast
9.North America Urinary Tract Infection Treatment Market Analysis
9.1. Market Value Forecast, By Country
9.1.1.Y-o-Y Growth Projections, By Country
9.1.2.Market Share & Basis Point (BPS) Analysis, By Country
9.1.3.Market Attractiveness Analysis, By Country
9.1.4.US
9.1.5.Canada
9.2. Market Value Forecast, By Drug Type
9.2.1.Y-o-Y Growth Projections, By Drug Type
9.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
9.2.3.Market Attractiveness Analysis, By Drug Type
9.2.4.Penicillin & Combinations
9.2.4.1. Amoxicillin
9.2.4.2. Amoxicillin+ Clavulanate Potassium
9.2.4.3. Others
9.2.5.Quinolones
9.2.5.1. Ciprofloxacin
9.2.5.2. Levofloxacin
9.2.5.3. Nalidixic acid
9.2.5.4. Norfloxacin
9.2.5.5. Others
9.2.6.Cephalosporin
9.2.6.1. Cefuroxime
9.2.6.2. Ceftriaxone
9.2.6.3. Cefixime
9.2.6.4. Cephalexin
9.2.7.Aminoglycoside Antibiotics
9.2.7.1. Amikacin
9.2.7.2. Gentamicin
9.2.8.Sulphonamides
9.2.8.1. Sulfamethoxazole + Trimethoprim
9.2.9.Azoles and Amphotericin B
9.2.10.Tetracycline
9.2.10.1. Doxycycline
9.2.11.Nitrofurans
9.2.11.1. Nitrofurantoin
9.2.12.Others
9.3. Market Value Forecast, By Distribution Channel
9.3.1.Y-o-Y Growth Projections, By Distribution Channel
9.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
9.3.3.Market Attractiveness Analysis, By Distribution Channel
9.3.4.Hospital Pharmacies
9.3.5.Gynecology and Urology Clinics
9.3.6.Drug Stores
9.3.7.Retail Pharmacies
9.3.8.Online Drug Stores
9.4. Market Value Forecast, By Indication
9.4.1.Y-o-Y Growth Projections, By Indication
9.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
9.4.3.Market Attractiveness Analysis, By Indication
9.4.4.Complicated UTI
9.4.5.Recurring Complicated UTI
9.4.6.Uncomplicated UTI
9.4.7.Neurogenic Bladder Infections
10. Latin America Urinary Tract Infection Treatment Market Analysis
10.1. Market Value Forecast, By Country
10.1.1.Y-o-Y Growth Projections, By Country
10.1.2.Market Share & Basis Point (BPS) Analysis, By Country
10.1.3.Market Attractiveness Analysis, By Country
10.1.4.Brazil
10.1.5.Mexico
10.1.6.Rest of Latin America
10.2. Market Value Forecast, By Drug Type
10.2.1.Y-o-Y Growth Projections, By Drug Type
10.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
10.2.3.Market Attractiveness Analysis, By Drug Type
10.2.4.Penicillin & Combinations
10.2.4.1. Amoxicillin
10.2.4.2. Amoxicillin+ Clavulanate Potassium
10.2.4.3. Others
10.2.5.Quinolones
10.2.5.1. Ciprofloxacin
10.2.5.2. Levofloxacin
10.2.5.3. Nalidixic acid
10.2.5.4. Norfloxacin
10.2.5.5. Others
10.2.6.Cephalosporin
10.2.6.1. Cefuroxime
10.2.6.2. Ceftriaxone
10.2.6.3. Cefixime
10.2.6.4. Cephalexin
10.2.7.Aminoglycoside Antibiotics
10.2.7.1. Amikacin
10.2.7.2. Gentamicin
10.2.8.Sulphonamides
10.2.8.1. Sulfamethoxazole + Trimethoprim
10.2.9.Azoles and Amphotericin B
10.2.10. Tetracycline
10.2.10.1.Doxycycline
10.2.11. Nitrofurans
10.2.11.1.Nitrofurantoin
10.2.12. Others
10.3. Market Value Forecast, By Distribution Channel
10.3.1.Y-o-Y Growth Projections, By Distribution Channel
10.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
10.3.3.Market Attractiveness Analysis, By Distribution Channel
10.3.4.Hospital Pharmacies
10.3.5.Gynecology and Urology Clinics
10.3.6.Drug Stores
10.3.7.Retail Pharmacies
10.3.8.Online Drug Stores
10.4. Market Value Forecast, By Indication
10.4.1.Y-o-Y Growth Projections, By Indication
10.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
10.4.3.Market Attractiveness Analysis, By Indication
10.4.4.Complicated UTI
10.4.5.Recurring Complicated UTI
10.4.6.Uncomplicated UTI
10.4.7.Neurogenic Bladder Infections
11. Western Europe Urinary Tract Infection Treatment Market Analysis
11.1. Market Value Forecast, By Country
11.1.1.Y-o-Y Growth Projections, By Country
11.1.2.Market Share & Basis Point (BPS) Analysis, By Country
11.1.3.Market Attractiveness Analysis, By Country
11.1.4.UK
11.1.5.Germany
11.1.6.France
11.1.7.Spain
11.1.8.Italy
11.1.9.Nordic
11.1.10. Benelux
11.1.11. Rest of Western Europe
11.2. Market Value Forecast, By Drug Type
11.2.1.Y-o-Y Growth Projections, By Drug Type
11.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
11.2.3.Market Attractiveness Analysis, By Drug Type
11.2.4.Penicillin & Combinations
11.2.4.1. Amoxicillin
11.2.4.2. Amoxicillin+ Clavulanate Potassium
11.2.4.3. Others
11.2.5.Quinolones
11.2.5.1. Ciprofloxacin
11.2.5.2. Levofloxacin
11.2.5.3. Nalidixic acid
11.2.5.4. Norfloxacin
11.2.5.5. Others
11.2.6.Cephalosporin
11.2.6.1. Cefuroxime
11.2.6.2. Ceftriaxone
11.2.6.3. Cefixime
11.2.6.4. Cephalexin
11.2.7.Aminoglycoside Antibiotics
11.2.7.1. Amikacin
11.2.7.2. Gentamicin
11.2.8.Sulphonamides
11.2.8.1. Sulfamethoxazole + Trimethoprim
11.2.9.Azoles and Amphotericin B
11.2.10. Tetracycline
11.2.10.1.Doxycycline
11.2.11. Nitrofurans
11.2.11.1.Nitrofurantoin
11.2.12. Others
11.3. Market Value Forecast, By Distribution Channel
11.3.1.Y-o-Y Growth Projections, By Distribution Channel
11.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
11.3.3.Market Attractiveness Analysis, By Distribution Channel
11.3.4.Hospital Pharmacies
11.3.5.Gynecology and Urology Clinics
11.3.6.Drug Stores
11.3.7.Retail Pharmacies
11.3.8.Online Drug Stores
11.4. Market Value Forecast, By Indication
11.4.1.Y-o-Y Growth Projections, By Indication
11.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
11.4.3.Market Attractiveness Analysis, By Indication
11.4.4.Complicated UTI
11.4.5.Recurring Complicated UTI
11.4.6.Uncomplicated UTI
11.4.7.Neurogenic Bladder Infections
12. Eastern Europe Urinary Tract Infection Treatment Market Analysis
12.1. Market Value Forecast, By Country
12.1.1.Y-o-Y Growth Projections, By Country
12.1.2.Market Share & Basis Point (BPS) Analysis, By Country
12.1.3.Market Attractiveness Analysis, By Country
12.1.4.Russia
12.1.5.Poland
12.1.6.Rest of Eastern Europe
12.2. Market Value Forecast, By Drug Type
12.2.1.Y-o-Y Growth Projections, By Drug Type
12.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
12.2.3.Market Attractiveness Analysis, By Drug Type
12.2.4.Penicillin & Combinations
12.2.4.1. Amoxicillin
12.2.4.2. Amoxicillin+ Clavulanate Potassium
12.2.4.3. Others
12.2.5.Quinolones
12.2.5.1. Ciprofloxacin
12.2.5.2. Levofloxacin
12.2.5.3. Nalidixic acid
12.2.5.4. Norfloxacin
12.2.5.5. Others
12.2.6.Cephalosporin
12.2.6.1. Cefuroxime
12.2.6.2. Ceftriaxone
12.2.6.3. Cefixime
12.2.6.4. Cephalexin
12.2.7.Aminoglycoside Antibiotics
12.2.7.1. Amikacin
12.2.7.2. Gentamicin
12.2.8.Sulphonamides
12.2.8.1. Sulfamethoxazole + Trimethoprim
12.2.9.Azoles and Amphotericin B
12.2.10. Tetracycline
12.2.10.1.Doxycycline
12.2.11. Nitrofurans
12.2.11.1.Nitrofurantoin
12.2.12. Others
12.3. Market Value Forecast, By Distribution Channel
12.3.1.Y-o-Y Growth Projections, By Distribution Channel
12.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
12.3.3.Market Attractiveness Analysis, By Distribution Channel
12.3.4.Hospital Pharmacies
12.3.5.Gynecology and Urology Clinics
12.3.6.Drug Stores
12.3.7.Retail Pharmacies
12.3.8.Online Drug Stores
12.4. Market Value Forecast, By Indication
12.4.1.Y-o-Y Growth Projections, By Indication
12.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
12.4.3.Market Attractiveness Analysis, By Indication
12.4.4.Complicated UTI
12.4.5.Recurring Complicated UTI
12.4.6.Uncomplicated UTI
12.4.7.Neurogenic Bladder Infections
13. APEJ Urinary Tract Infection Treatment Market Analysis
13.1. Market Value Forecast, By Country
13.1.1.Y-o-Y Growth Projections, By Country
13.1.2.Market Share & Basis Point (BPS) Analysis, By Country
13.1.3.Market Attractiveness Analysis, By Country
13.1.4.China
13.1.5.India
13.1.6.ASEAN
13.1.7.Australia & New Zealand
13.1.8.Rest of APEJ
13.2. Market Value Forecast, By Drug Type
13.2.1.Y-o-Y Growth Projections, By Drug Type
13.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
13.2.3.Market Attractiveness Analysis, By Drug Type
13.2.4.Penicillin & Combinations
13.2.4.1. Amoxicillin
13.2.4.2. Amoxicillin+ Clavulanate Potassium
13.2.4.3. Others
13.2.5.Quinolones
13.2.5.1. Ciprofloxacin
13.2.5.2. Levofloxacin
13.2.5.3. Nalidixic acid
13.2.5.4. Norfloxacin
13.2.5.5. Others
13.2.6.Cephalosporin
13.2.6.1. Cefuroxime
13.2.6.2. Ceftriaxone
13.2.6.3. Cefixime
13.2.6.4. Cephalexin
13.2.7.Aminoglycoside Antibiotics
13.2.7.1. Amikacin
13.2.7.2. Gentamicin
13.2.8.Sulphonamides
13.2.8.1. Sulfamethoxazole + Trimethoprim
13.2.9.Azoles and Amphotericin B
13.2.10. Tetracycline
13.2.10.1.Doxycycline
13.2.11. Nitrofurans
13.2.11.1.Nitrofurantoin
13.2.12. Others
13.3. Market Value Forecast, By Distribution Channel
13.3.1.Y-o-Y Growth Projections, By Distribution Channel
13.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
13.3.3.Market Attractiveness Analysis, By Distribution Channel
13.3.4.Hospital Pharmacies
13.3.5.Gynecology and Urology Clinics
13.3.6.Drug Stores
13.3.7.Retail Pharmacies
13.3.8.Online Drug Stores
13.4. Market Value Forecast, By Indication
13.4.1.Y-o-Y Growth Projections, By Indication
13.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
13.4.3.Market Attractiveness Analysis, By Indication
13.4.4.Complicated UTI
13.4.5.Recurring Complicated UTI
13.4.6.Uncomplicated UTI
13.4.7.Neurogenic Bladder Infections
14. Japan Urinary Tract Infection Treatment Market Analysis
14.1. Market Value Forecast, By Drug Type
14.1.1.Y-o-Y Growth Projections, By Drug Type
14.1.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
14.1.3.Market Attractiveness Analysis, By Drug Type
14.1.4.Penicillin & Combinations
14.1.4.1. Amoxicillin
14.1.4.2. Amoxicillin+ Clavulanate Potassium
14.1.4.3. Others
14.1.5.Quinolones
14.1.5.1. Ciprofloxacin
14.1.5.2. Levofloxacin
14.1.5.3. Nalidixic acid
14.1.5.4. Norfloxacin
14.1.5.5. Others
14.1.6.Cephalosporin
14.1.6.1. Cefuroxime
14.1.6.2. Ceftriaxone
14.1.6.3. Cefixime
14.1.6.4. Cephalexin
14.1.7.Aminoglycoside Antibiotics
14.1.7.1. Amikacin
14.1.7.2. Gentamicin
14.1.8.Sulphonamides
14.1.8.1. Sulfamethoxazole + Trimethoprim
14.1.9.Azoles and Amphotericin B
14.1.10. Tetracycline
14.1.10.1.Doxycycline
14.1.11. Nitrofurans
14.1.11.1.Nitrofurantoin
14.1.12. Others
14.2. Market Value Forecast, By Distribution Channel
14.2.1.Y-o-Y Growth Projections, By Distribution Channel
14.2.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
14.2.3.Market Attractiveness Analysis, By Distribution Channel
14.2.4.Hospital Pharmacies
14.2.5.Gynecology and Urology Clinics
14.2.6.Drug Stores
14.2.7.Retail Pharmacies
14.2.8.Online Drug Stores
14.3. Market Value Forecast, By Indication
14.3.1.Y-o-Y Growth Projections, By Indication
14.3.2.Market Share & Basis Point (BPS) Analysis, By Indication
14.3.3.Market Attractiveness Analysis, By Indication
14.3.4.Complicated UTI
14.3.5.Recurring Complicated UTI
14.3.6.Uncomplicated UTI
14.3.7.Neurogenic Bladder Infections
15. MEA Urinary Tract Infection Treatment Market Analysis
15.1. Market Value Forecast, By Country
15.1.1.Y-o-Y Growth Projections, By Country
15.1.2.Market Share & Basis Point (BPS) Analysis, By Country
15.1.3.Market Attractiveness Analysis, By Country
15.1.4.GCC Countries
15.1.5.South Africa
15.1.6.North Africa
15.1.7.Rest of MEA
15.2. Market Value Forecast, By Drug Type
15.2.1.Y-o-Y Growth Projections, By Drug Type
15.2.2.Market Share & Basis Point (BPS) Analysis, By Drug Type
15.2.3.Market Attractiveness Analysis, By Drug Type
15.2.4.Penicillin & Combinations
15.2.4.1. Amoxicillin
15.2.4.2. Amoxicillin+ Clavulanate Potassium
15.2.4.3. Others
15.2.5.Quinolones
15.2.5.1. Ciprofloxacin
15.2.5.2. Levofloxacin
15.2.5.3. Nalidixic acid
15.2.5.4. Norfloxacin
15.2.5.5. Others
15.2.6.Cephalosporin
15.2.6.1. Cefuroxime
15.2.6.2. Ceftriaxone
15.2.6.3. Cefixime
15.2.6.4. Cephalexin
15.2.7.Aminoglycoside Antibiotics
15.2.7.1. Amikacin
15.2.7.2. Gentamicin
15.2.8.Sulphonamides
15.2.8.1. Sulfamethoxazole + Trimethoprim
15.2.9.Azoles and Amphotericin B
15.2.10. Tetracycline
15.2.10.1.Doxycycline
15.2.11. Nitrofurans
15.2.11.1.Nitrofurantoin
15.2.12. Others
15.3. Market Value Forecast, By Distribution Channel
15.3.1.Y-o-Y Growth Projections, By Distribution Channel
15.3.2.Market Share & Basis Point (BPS) Analysis, By Distribution Channel
15.3.3.Market Attractiveness Analysis, By Distribution Channel
15.3.4.Hospital Pharmacies
15.3.5.Gynecology and Urology Clinics
15.3.6.Drug Stores
15.3.7.Retail Pharmacies
15.3.8.Online Drug Stores
15.4. Market Value Forecast, By Indication
15.4.1.Y-o-Y Growth Projections, By Indication
15.4.2.Market Share & Basis Point (BPS) Analysis, By Indication
15.4.3.Market Attractiveness Analysis, By Indication
15.4.4.Complicated UTI
15.4.5.Recurring Complicated UTI
15.4.6.Uncomplicated UTI
15.4.7.Neurogenic Bladder Infections
16. Competition Landscape
16.1. Competition Dashboard
16.2. Company Profiles Inclusions
16.2.1.Revenue
16.2.2.Products/Brand Offerings
16.2.3.Key developments
16.2.4.SWOT Analysis
16.3. Company Profiled
16.3.1.Johnson & Johnson Private Ltd.
16.3.2.Boehringer Ingelheim GmbH
16.3.3.Cipla Ltd.
16.3.4.Bayer AG
16.3.5.GlaxoSmithKline Pharmaceuticals Ltd.
16.3.6.Pfizer Inc.
16.3.7.F. Hoffmann–La Roche Ltd.
16.3.8.Novartis AG
16.3.9.AstraZeneca plc
Urinary Tract Infections Market Reports - List of Tables
Table 1: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 2: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 3: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2016–2026
Table 4: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026
Table 5: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Region, 2016–2026
Table 6: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026
Table 7: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 8: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 9: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026
Table 10: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026
Table 11: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026
Table 12: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 13: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 14: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026
Table 15: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026
Table 16: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026
Table 17: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 18: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 19: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026
Table 20: Western Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026
Table 21: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026
Table 22: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 23: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 24: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026
Table 25: Eastern Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026
Table 26: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026
Table 27: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 28: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 29: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026
Table 30: APEJ Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026
Table 31: Japan Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 32: Japan Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 33: Japan Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026
Table 34: Japan Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026
Table 35: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Country, 2016–2026
Table 36: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 37: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2016–2026
Table 38: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast By Distribution Channel, 2016–2026
Table 39: MEA Urinary Tract Infection Treatment Market Value (US$ Mn) Analysis and Forecast By Indication, 2016–2026
Urinary Tract Infections Market Reports - List of Figures
Figure 1: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast 2016 and 2026
Figure 2: Global Urinary Tract Infection Treatment Market Split By Region (2016)
Figure 3: Global Urinary Tract Infection Treatment Market Split By Drug Type (2016)
Figure 4: Global Urinary Tract Infection Treatment Market Split By Distribution Channel (2016)
Figure 5: Global Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026
Figure 6: Global Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026
Figure 7: Global Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026
Figure 8: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Penicillin & Combinations Segment, 2016–2026
Figure 9: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Quinolones Segment, 2016–2026
Figure 10: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Cephalosporin Segment, 2016–2026
Figure 11: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Aminoglycoside Antibiotics Segment, 2016–2026
Figure 12: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Sulphonamides Segment, 2016–2026
Figure 13: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Azoles and Amphotericin B Segment, 2016–2026
Figure 14: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Tetracycline Segment, 2016–2026
Figure 15: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Nitrofurans Segment, 2016–2026
Figure 16: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Other Drug Type Segment, 2016–2026
Figure 17: Global Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026
Figure 18: Global Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026
Figure 19: Global Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026
Figure 20: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Hospital Pharmacies Segment, 2016–2026
Figure 21: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Gynecology and Urology Clinics Segment, 2016–2026
Figure 22: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Drug Stores Segment, 2016–2026
Figure 23: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Retail Pharmacies Segment, 2016–2026
Figure 24: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Online Drug Stores Segment, 2016–2026
Figure 25: Global Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026
Figure 26: Global Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026
Figure 27: Global Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026
Figure 28: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Complicated UTI Segment, 2016–2026
Figure 29: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Recurring Complicated UTI Segment, 2016–2026
Figure 30: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Uncomplicated UTI Segment, 2016–2026
Figure 31: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Neurogenic Bladder Infections Segment, 2016–2026
Figure 32: Global Urinary Tract Infection Treatment Share Analysis (%) By Region, 2016 & 2026
Figure 33: Global Urinary Tract Infection Treatment Attractiveness Analysis By Region, 2016–2026
Figure 34: Global Urinary Tract Infection Treatment Y-o-Y growth (%) By Region, 2016–2026
Figure 35: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By North America, 2016–2026
Figure 36: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Latin America, 2016–2026
Figure 37: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Western Europe, 2016–2026
Figure 38: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Eastern Europe, 2016–2026
Figure 39: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By APEJ, 2016–2026
Figure 40: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By Japan, 2016–2026
Figure 41: Global Urinary Tract Infection Treatment Market Absolute $ Opportunity (US$ Mn) By MEA, 2016–2026
Figure 42: North America Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026
Figure 43: North America Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026
Figure 44: North America Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026
Figure 45: North America Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026
Figure 46: North America Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026
Figure 47: North America Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026
Figure 48: North America Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026
Figure 49: North America Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026
Figure 50: North America Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026
Figure 51: North America Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026
Figure 52: North America Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026
Figure 53: North America Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026
Figure 54: Latin America Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026
Figure 55: Latin America Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026
Figure 56: Latin America Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026
Figure 57: Latin America Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026
Figure 58: Latin America Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026
Figure 59: Latin America Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026
Figure 60: Latin America Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026
Figure 61: Latin America Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026
Figure 62: Latin America Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026
Figure 63: Latin America Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026
Figure 64: Latin America Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026
Figure 65: Latin America Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026
Figure 66: Western Europe Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026
Figure 67: Western Europe Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026
Figure 68: Western Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026
Figure 69: Western Europe Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026
Figure 70: Western Europe Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026
Figure 71: Western Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026
Figure 72: Western Europe Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026
Figure 73: Western Europe Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026
Figure 74: Western Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026
Figure 75: Western Europe Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026
Figure 76: Western Europe Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026
Figure 77: Western Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026
Figure 78: Eastern Europe Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026
Figure 79: Eastern Europe Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026
Figure 80: Eastern Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026
Figure 81: Eastern Europe Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026
Figure 82: Eastern Europe Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026
Figure 83: Eastern Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026
Figure 84: Eastern Europe Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026
Figure 85: Eastern Europe Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026
Figure 86: Eastern Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026
Figure 87: Eastern Europe Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026
Figure 88: Eastern Europe Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026
Figure 89: Eastern Europe Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026
Figure 90: APEJ Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026
Figure 91: APEJ Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026
Figure 92: APEJ Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026
Figure 93: APEJ Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026
Figure 94: APEJ Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026
Figure 95: APEJ Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026
Figure 96: APEJ Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026
Figure 97: APEJ Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026
Figure 98: APEJ Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026
Figure 99: APEJ Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026
Figure 100: APEJ Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026
Figure 101: APEJ Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026
Figure 102: Japan Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026
Figure 103: Japan Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026
Figure 104: Japan Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026
Figure 105: Japan Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026
Figure 106: Japan Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026
Figure 107: Japan Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026
Figure 108: Japan Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026
Figure 109: Japan Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026
Figure 110: Japan Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026
Figure 111: MEA Urinary Tract Infection Treatment Share Analysis (%) By Country, 2016 & 2026
Figure 112: MEA Urinary Tract Infection Treatment Attractiveness Analysis By Country, 2016–2026
Figure 113: MEA Urinary Tract Infection Treatment Y-o-Y growth (%) By Country, 2016–2026
Figure 114: MEA Urinary Tract Infection Treatment Share Analysis (%) By Drug Type, 2016 & 2026
Figure 115: MEA Urinary Tract Infection Treatment Attractiveness Analysis By Drug Type, 2016–2026
Figure 116: MEA Urinary Tract Infection Treatment Y-o-Y growth (%) By Drug Type, 2016–2026
Figure 117: MEA Urinary Tract Infection Treatment Share Analysis (%) By Distribution Channel, 2016 & 2026
Figure 118: MEA Urinary Tract Infection Treatment Attractiveness Analysis By Distribution Channel, 2016–2026
Figure 119: MEA Urinary Tract Infection Treatment Y-o-Y growth (%) By Distribution Channel, 2016–2026
Figure 120: MEA Urinary Tract Infection Treatment Share Analysis (%) By Indication, 2016 & 2026
Figure 121: MEA Urinary Tract Infection Treatment Attractiveness Analysis By Indication, 2016–2026
Figure 122: MEA Urinary Tract Infection Treatment Y-o-Y growth (%) By Indication, 2016–2026